Advertisement

Der Ophthalmologe

, Volume 115, Issue 10, pp 842–854 | Cite as

Stellungnahme von BVA, DOG und RG zur intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss

Therapeutische Strategien, Stand 24.04.2018
  • Berufsverband der Augenärzte Deutschlands e. V. (BVA)
  • Deutsche Ophthalmologische Gesellschaft (DOG)
  • Retinologische Gesellschaft e. V. (RG)
Leitlinien, Stellungnahmen und Empfehlungen
  • 102 Downloads

Empfehlungen/Statements

5-1: Indikationsstellung

  • Beim retinalen Venenverschluss (RVV) sollen initial folgende Untersuchungen erfolgen: bestkorrigierter Visus, Untersuchung auf Rubeosis iridis in Miosis (insbesondere bei Zentralvenenverschluss [ZVV]), Untersuchung der gesamten Netzhaut in Mydriasis, optische Kohärenztomographie (OCT), Augeninnendruckmessung.

  • Eine Fluoreszeinangiographie (FAG) soll erfolgen, sobald die Netzhaut ausreichend beurteilbar erscheint, spätestens nach 4 Monaten.

    Empfehlungsgrad: ⇑⇑

  • Eine Behandlung mit intravitrealen Medikamenten (IVOM) soll bei RVV-Patienten nur bei Nachweis eines verschlussinduzierten Makulaödems mit Visusminderung begonnen werden, bei dem aufgrund des Befundes eine funktionelle und morphologische Verbesserung erwartet werden kann. Der Beginn dieser Behandlung soll zeitnah nach Diagnosestellung erfolgen.

    Empfehlungsgrad: ⇑⇑

  • IVOM-Folgebehandlungen bzw. Folgeserien sollen nur bei Vorliegen eines verschlussinduzierten Makulaödems mit...

Statement of the Professional Association of Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on intravitreal treatment of vision-reducing macular edema by retinal vein occlusion

Treatment strategies, status 24 April 2018

Notes

Redaktionskomitee

Prof. Dr. Hansjürgen Agostini, Freiburg

Prof. Dr. Bernd Bertram, Aachen

Prof. Dr. Norbert Bornfeld, Essen

Dr. Martin Bresgen, Köln

Prof. Dr. Nicolas Feltgen, Göttingen (federführend)

Prof. Dr. Lars-Olaf Hattenbach, Ludwigshafen

Prof. Dr. Horst Helbig, Regensburg

Prof. Dr. Hans Hoerauf, Göttingen

Prof. Dr. Frank G. Holz, Bonn

Prof. Dr. Gabriele E. Lang, Ulm

Prof. Dr. Daniel Pauleikhoff, Münster

Dr. Amelie Pielen, Hannover

PD Dr. Matus Rehak, Leipzig

Prof. Dr. Focke Ziemssen, Tübingen

Einhaltung ethischer Richtlinien

Interessenkonflikt

Siehe Tab. 1 im Anhang.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Supplementary material

347_2018_775_MOESM1_ESM.pdf (1.1 mb)
Datentabelle zur Stellungnahme von BVA, DOG und RG zur Intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss

Literatur

Verwendete Literatur

  1. 1.
    Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte Deutschlands (2010) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss. Ophthalmologe 107:583–596CrossRefGoogle Scholar
  2. 2.
    Ehlers JP, Kim SJ, Yeh S, Thorne JE, Mruthyunjaya P, Schoenberger SD et al (2017) Therapies for macular edema associated with branch retinal vein occlusion: a report by the American academy of ophthalmology. Ophthalmology 124(9):1412–1423CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Berger AR, Cruess AF, Altomare F, Chaudhary V, Colleaux K, Greve M et al (2015) Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica 234(1):6–25CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW (2016) Retinal vein occlusions preferred practice pattern(®) guidelines. Ophthalmology 123(1):P182–P208CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS ONE 8(10):e78538CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Mir TA, Kherani S, Hafiz G, Scott AW, Zimmer-Galler I, Wenick AS et al (2016) Changes in retinal Nonperfusion associated with suppression of vascular Endothelial growth factor in retinal vein occlusion. Ophthalmology 123(3):625–634CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R et al (2016) Intravitreal Aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123(2):330–336CrossRefGoogle Scholar
  8. 8.
    Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL et al (2014) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina (Philadelphia, Pa) 34(9):1728–1735CrossRefGoogle Scholar
  9. 9.
    Thach AB, Yau L, Hoang C, Tuomi L (2014) Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 121(5):1059–1066CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Hattenbach L‑O, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N et al (2018) Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol (copenh) 96(1):e10–e8CrossRefGoogle Scholar
  11. 11.
    Hoerauf H, Feltgen N, Weiss C, Paulus E‑M, Schmitz-Valckenberg S, Pielen A et al (2016) Clinical efficacy and safety of Ranibizumab versus Dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol 169:258–267CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC et al (2017) Effect of Bevacizumab vs Aflibercept on visual acuity among patients with macular edema Due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 317(20):2072–2087CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH et al (2015) A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol 99(7):954–959CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Gado AS, Macky TA (2014) Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Exp Ophthalmol 42(7):650–655CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Lotfy A, Solaiman KAM, Abdelrahman A, Samir A (2017) EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Retina (Philadelphia, Pa).  https://doi.org/10.1097/iae.0000000000001782 CrossRefGoogle Scholar
  16. 16.
    Rajagopal R, Shah GK, Blinder KJ, Altaweel M, Eliott D, Wee R et al (2015) Bevacizumab versus Ranibizumab in the treatment of macular edema Due to retinal vein occlusion: 6‑month results of the CRAVE study. Ophthalmic Surg lasers imaging. Retina 46(8):844–850Google Scholar
  17. 17.
    Bandello F, Augustin A, Tufail A, Leaback R (2018) A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol.  https://doi.org/10.1177/1120672117750058 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yoon YH, Kim JW, Lee JY, Kim IT, Kang SW, Yu HG et al (2018) Dexamethasone Intravitreal implant for early treatment and retreatment of macular edema related to branch retinal vein occlusion: the Multicenter COBALT study. Ophthalmologica 240(2):81–89.  https://doi.org/10.1159/000487547 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Goñi FJ, Stalmans I, Denis P, Nordmann J‑P, Taylor S, Diestelhorst M et al (2016) Elevated Intraocular pressure after Intravitreal steroid injection in diabetic macular edema: monitoring and management. Ophthalmol Ther 5(1):47–61CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ (2017) Trends of anti-vascular Endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients. Ophthalmology 124(3):352–358CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Wang MD, Jeng-Miller KW, Feng HL, Prenner JL, Fine HF, Shah SP (2016) Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselves. Br J Ophthalmol 100(10):1332–1336CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Mishra SK, Gupta A, Patyal S, Kumar S, Raji K, Singh A et al (2018) Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. Int J Retina Vitreous 4(1):13.  https://doi.org/10.1186/s40942-018-0114-2 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kube T, Sutter M, Trittler R, Feltgen N, Hansen LL, Agostini HT (2006) Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol 244:1385–1390CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Bressler NM (2017) Treatment of macular edema Due to central retinal vein occlusion: another score for repackaged Bevacizumab. JAMA 317(20):2067–2069.  https://doi.org/10.1001/jama.2017.5899 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118(10):2041–2049CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L et al (2014) Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 121(12):2432–2442CrossRefGoogle Scholar
  28. 28.
    Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S et al (2016) Individualized stabilization criteria-driven Ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 123(6):1332–1344CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Korobelnik J‑F, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U et al (2014) Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202–208CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‑year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429–437CrossRefPubMedCentralGoogle Scholar
  31. 31.
    Ziemssen F, Bertelmann T, Hufenbach U, Scheffler M, Liakopoulos S, Schmitz-Valckenberg S (2016) Delayed treatment initiation of more than 2 weeks : Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study). Ophthalmologe 113(2):143–151CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Dirani A, Mantel I, Ambresin A (2015) Recurrent macular edema in central retinal vein occlusion treated with Intravitreal Ranibizumab using a modified treat and extend regimen. Klin Monbl Augenheilkd 232(4):538–541CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Freund KB, Korobelnik J‑F, Devenyi R, Framme C, Galic J, Herbert E et al (2015) TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: a literature review and consensus recommendations. Retina (Philadelphia, Pa) 35(8):1489–1506CrossRefGoogle Scholar
  34. 34.
    Hufendiek K, Pielen A, Framme C (2017) Injektionsstrategien bei der Anwendung intravitrealer VEGF-Inhibitoren: „Pro Re Nata versus Treat and Extend“. Klin Monbl Augenheilkd 235(8):930–939.  https://doi.org/10.1055/s-0042-122340 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R et al (2016) Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123(5):1101–1111CrossRefPubMedCentralGoogle Scholar
  36. 36.
    Wai KM, Khan M, Srivastava S, Rachitskaya A, Silva FQ, Deasy R et al (2017) Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice. Br J Ophthalmol 101(5):574–579CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Wecker T, Ehlken C, Bühler A, Lange C, Agostini H, Böhringer D et al (2017) Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 101(3):353–359PubMedPubMedCentralGoogle Scholar
  38. 38.
    Eter N, Mohr A, Wachtlin J, Feltgen N, Shirlaw A, Leaback R et al (2017) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 255(1):77–87CrossRefPubMedCentralGoogle Scholar
  39. 39.
    Callizo J, Schmitz-Valckenberg S, Spital G, Liakopoulos S, Bertelmann T, Voegeler J et al (2017) Erläuterung des Behandlungserfolges bei RVV-Patienten mit VEGF Inhibition in einer prospektiven, nicht-interventionellen Studie über 12 Monate. DOG, Berlin (Retina: Intravitreale Injektionen)Google Scholar
  40. 40.
    Feltgen N, Ziemssen F, Spital G, Liakopoulos S, Voegeler J, Koch M et al (2017) Analysis of baseline factors affecting outcome of RVO patients to ranibizumab therapy in a prospective, non-interventional trial (OCEAN study). EURETINA, Barcelona (Vascular Diseases and Diabetc Retinopathy)Google Scholar
  41. 41.
    Korobelnik J‑F, Kodjikian L, Delcourt C, Gualino V, Leaback R, Pinchinat S et al (2016) Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 254(12):2307–2318CrossRefPubMedCentralGoogle Scholar
  42. 42.
    Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127:1101–1114 (Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5)CrossRefPubMedCentralGoogle Scholar
  43. 43.
    Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E et al (2017) Sustained benefits of Ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology 124(12):1778–1787CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Pielen A, Mirshahi A, Feltgen N, Lorenz K, Korb C, Junker B et al (2015) Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol (copenh) 93(1):e29–e37CrossRefGoogle Scholar
  45. 45.
    Leitritz MA, Gelisken F, Ziemssen F, Szurman P, Bartz-Schmidt KU, Jaissle GB (2013) Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol 97(2):215–219CrossRefPubMedCentralGoogle Scholar
  46. 46.
    Lam FC, Chia SN, Lee RMH (2015) Macular grid laser photocoagulation for branch retinal vein occlusion. Cochrane Database Syst Rev 11(5):CD8732.  https://doi.org/10.1002/14651858.cd008732.pub2 CrossRefGoogle Scholar
  47. 47.
    Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C (2012) Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 22(4):607–614CrossRefPubMedCentralGoogle Scholar
  48. 48.
    Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina (Philadelphia, Pa) 29:511–515CrossRefGoogle Scholar
  49. 49.
    Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA et al (2014) Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol 157(1):237–247CrossRefPubMedCentralGoogle Scholar
  50. 50.
    The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98(3):271–282.  https://doi.org/10.1016/0002-9394(84)90316-7 CrossRefGoogle Scholar
  51. 51.
    Tomiyasu T, Hirano Y, Yoshida M, Suzuki N, Nishiyama T, Uemura A et al (2016) Microaneurysms cause refractory macular edema in branch retinal vein occlusion. Sci Rep 6(1):29445.  https://doi.org/10.1038/srep29445 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Gozawa M, Takamura Y, Miyake S, Matsumura T, Morioka M, Yamada Y et al (2017) Photocoagulation of the retinal Nonperfusion area prevents the expression of the vascular Endothelial growth factor in an animal model. Invest Ophthalmol Vis Sci 58(13):5946–5953CrossRefPubMedCentralGoogle Scholar
  53. 53.
    Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I et al (2015) Scatter Photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 122(7):1426–1437CrossRefPubMedCentralGoogle Scholar
  54. 54.
    Wykoff CC, Ou WC, Wang R, Brown DM, Cone C, Zamora D et al (2017) Peripheral laser for recalcitrant macular edema owing to retinal vein occlusion: the WAVE trial. Ophthalmology 124(6):919–921CrossRefPubMedCentralGoogle Scholar
  55. 55.
    Rehak M, Tilgner E, Franke A, Rauscher FG, Brosteanu O, Wiedemann P (2014) Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol 252(5):745–752CrossRefPubMedCentralGoogle Scholar
  56. 56.
    Tomomatsu Y, Tomomatsu T, Takamura Y, Gozawa M, Arimura S, Takihara Y et al (2016) Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmol (copenh) 94(3):e225–e230CrossRefGoogle Scholar

Weiterführende Literatur

  1. 57.
    Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809CrossRefGoogle Scholar
  2. 58.
    Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R et al (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122(3):538–544CrossRefGoogle Scholar
  3. 59.
    Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453–2460CrossRefPubMedCentralGoogle Scholar
  4. 60.
    Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146CrossRefGoogle Scholar
  5. 61.
    Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124–1133CrossRefPubMedCentralGoogle Scholar
  6. 62.
    Kreutzer TC, Wolf A, Dirisamer M, Strauss RW, Foerster P, Feltgen N et al (2015) Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial. Ophthalmologica 233(1):8–17CrossRefPubMedCentralGoogle Scholar
  7. 63.
    Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ et al (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121(7):1414–1420CrossRefPubMedCentralGoogle Scholar
  8. 64.
    Epstein DLJ, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119(6):1184–1189CrossRefPubMedCentralGoogle Scholar
  9. 65.
    Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119(12):2587–2591CrossRefPubMedCentralGoogle Scholar
  10. 66.
    Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH et al (2010) Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 150(3):310–314CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Berufsverband der Augenärzte Deutschlands e. V. (BVA)
    • 1
  • Deutsche Ophthalmologische Gesellschaft (DOG)
    • 2
  • Retinologische Gesellschaft e. V. (RG)
    • 3
  1. 1.Berufsverband der Augenärzte Deutschlands e. V.DüsseldorfDeutschland
  2. 2.Deutsche Ophthalmologische GesellschaftMünchenDeutschland
  3. 3.Retinologische Gesellschaft e. V.FreiburgDeutschland

Personalised recommendations